A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of ASP7035 in Patients with Nocturia Associated with Norturnal Polyuria

Trial Profile

A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of ASP7035 in Patients with Nocturia Associated with Norturnal Polyuria

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs ASP 7035 (Primary)
  • Indications Nocturia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Tacurion Pharma
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 26 Jul 2014 Status changed from planning to recruiting, as per European Clinical Trials Database record.
    • 14 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top